Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types | MicrobiomeTrials← Back to trialsNCT06075524
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
RecruitingOBSERVATIONAL
Trial Details
Start: 2015-06-15Est. Completion: 2028-12-31
Enrollment target: 500 participants Locations- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Other microbiome trials you might be interested in
Advanced MelanomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Melanoma of Unknown PrimaryPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Pathologic Stage IV Cutaneous Melanoma AJCC v8Unresectable Acral Lentiginous MelanomaUnresectable MelanomaUnresectable Mucosal Melanoma
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy …
Fairhope, United StatesEst. completion Jan 31, 2027
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaRecurrent MelanomaUnresectable Melanoma
This phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trameti…
Birmingham, United StatesEst. completion Sep 30, 2023